Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States

References

• Lanktree MB, Chapman AB. Autosomal dominant polycystic kidney disease. CMAJ. 2017;189(45):E1396.
   PubMed Web of Science ®Google Scholar
• Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet (London, England). 2015;385(9981):1993–2002.
   PubMed Web of Science ®Google Scholar
• Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011;364(16):1533–1543.
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities 2018 [cited 2020 April 6]. Available from: https://www.usrds.org/2018/download/2018_Volume_2_ESRD_in_the_US.pdf.
   Google Scholar
• Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122–2130.
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006–1013.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25(11):2399–2418.
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942–951.
   PubMed Web of Science ®Google Scholar
• Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int. 2009;75(2):235–241.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Liang C, Lubeck DP, et al. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context. 2015;4:212275.
   PubMedGoogle Scholar
• McEwan P, Bennett Wilton H, Ong ACM, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol. 2018;19(1):37.
   PubMed Web of Science ®Google Scholar
• McGovern AP, Jones S, van Vlymen J, et al. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol. 2014;15:182.
   PubMed Web of Science ®Google Scholar
• Neumann HP, Jilg C, Bacher J, Else-Kroener-Fresenius-ADPKD-Registry, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28(6):1472–1487.
   PubMed Web of Science ®Google Scholar
• Solazzo A, Testa F, Giovanella S, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS One. 2018;13(1):e0190430.
   PubMed Web of Science ®Google Scholar
• Willey CJ, Blais JD, Hall AK, et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356–1363.
   PubMed Web of Science ®Google Scholar
• Willey CJ, Kamat S, Stellhorn R, et al. Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013–2015. Kidney Dis (Basel). 2019;5(2):107–117.
   PubMed Web of Science ®Google Scholar
• Croft JB, Wheaton AG, Liu Y, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease – United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(7):205–211.
   PubMed Web of Science ®Google Scholar
• Mantri S, Fullard ME, Beck J, et al. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. NPJ Parkinsons Dis. 2019;5:1.
   PubMed Web of Science ®Google Scholar
• Ward BW, Black LI. State and regional prevalence of diagnosed multiple chronic conditions among adults aged ≥18 years – United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(29):735–738.
   PubMed Web of Science ®Google Scholar
• Knight T, Schaefer C, Krasa H, et al. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. Clinicecon Outcome Res. 2015;7:123–132.
   PubMed Web of Science ®Google Scholar
• Brown L, Cai T, DasGupta A. Interval estimation for a binomial proportion. Statist Sci. 2001;16(2):101–117.
   Web of Science ®Google Scholar
• United States Census Bureau. 2010. Census 2010. [Accessed 2020 January 17]. Available from: https://www.census.gov/.
   Google Scholar
• Meit M, Knudson A, Gilbert T, et al. The 2014 update of the rural-urban chartbook. Rural Health Reform Policy Research Center. 2014;1–153.
   Google Scholar
• Inoue R, Nishi H, Inoue D, et al. Regional variance of the early use of tolvaptan for autosomal dominant polycystic kidney disease. Kidney360. 2020;1(8):740–745.
   PubMedGoogle Scholar
• Blankart CR. Does healthcare infrastructure have an impact on delay in diagnosis and survival? Health Policy. 2012;105(2–3):128–137.
   PubMed Web of Science ®Google Scholar
• Zahnd WE, Fogleman AJ, Jenkins WD. Rural-urban disparities in stage of diagnosis among cancers with preventive opportunities. Am J Prev Med. 2018;54(5):688–698.
   PubMed Web of Science ®Google Scholar
• Bowe B, Xie Y, Li T, et al. Changes in the US burden of chronic kidney disease from 2002 to 2016: an analysis of the Global Burden of Disease Study. JAMA Netw Open. 2018;1(7):e184412.
   PubMed Web of Science ®Google Scholar
• Samanic CM, Barbour KE, Liu Y, et al. Prevalence of self-reported hypertension and antihypertensive medication use among adults - United States, 2017. MMWR Morb Mortal Wkly Rep. 2020;69(14):393–398.
   PubMed Web of Science ®Google Scholar
• Centre for Disease Control and Prevention. Adult Obesity Prevalence Maps 2019. [cited 2020 July 3]. Available from: https://www.cdc.gov/obesity/data/prevalence-maps.html.
   Google Scholar
• Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.
   PubMed Web of Science ®Google Scholar
• Otsuka. Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD) 2018. [cited 2019 November 11]. Available from: https://www.otsuka-us.com/discover/articles-1188.
   Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Manceur AM, Guerin A, et al. The societal economic burden of autosomal dominant polycystic kidney disease in the United States. BMC Health Serv Res. 2020;20(1):126.
   PubMed Web of Science ®Google Scholar
• United States Census Bureau. Overview of Race and Hispanic Origin: 2010. 2011. [cited 2020 October 15]. Available from: https://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf.
   Google Scholar
• Murphy EL, Dai F, Blount KL, et al. Revisiting racial differences in ESRD due to ADPKD in the United States. BMC Nephrol. 2019;20(1):55.
   PubMed Web of Science ®Google Scholar
• Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol. 2008;19(7):1261–1270.
   PubMed Web of Science ®Google Scholar
• Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458–2470.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337–348.
   PubMed Web of Science ®Google Scholar